본문 바로가기
KERD
논문KCI 등재

Prolonged QT Interval in Cirrhosis: Twisting Time?

Lee William|Vandenberk Bert|Raj Satish R.|Lee Samuel S.
거트앤리버 소화기연관학회협의회|2022.11|Gut and Liver|제16권 제6호|pp. 849-860|DOI 10.5009/gnl210537

1

조회

0

다운로드

0

인용

0

참고문헌

키워드

CirrhosisTorsade de pointesDrug interactionAcquired long QT syndromeVentricular repolarization

초록

Approximately 30% to 70% of patients with cirrhosis have QT interval prolongation. In patients without cirrhosis, QT prolongation is associated with an increased risk of ventricular arrhythmias, such as torsade de pointes (TdP). In cirrhotic patients, there is likely a significant association between the corrected QT (QTc) interval and the severity of liver disease, and possibly with increased mortality. We present a stepwise overview of the pathophysiology and management of acquired long QT syndrome in cirrhosis. The QT interval is mainly determined by ventricular repolarization. To compare the QT interval in time it should be corrected for heart rate (QTc), preferably by the Fridericia method. A QTc interval >450 ms in males and >470 ms in females is considered prolonged. The pathophysiological mechanism remains incompletely understood, but may include metabolic, autonomic or hormonal imbalances, cirrhotic heart failure and/or genetic predisposition. Additional external risk factors for QTc prolongation include medication (IKr blockade and altered cytochrome P450 activity), bradycardia, electrolyte abnormalities, underlying cardiomyopathy and acute illness. In patients with cirrhosis, multiple hits and cardiac-hepatic interactions are often required to sufficiently erode the repolarization reserve before long QT syndrome and TdP can occur. While some risk factors are unavoidable, overall risk can be mitigated by electrocardiogram monitoring and avoiding drug interactions and electrolyte and acid-base disturbances. In cirrhotic patients with prolonged QTc interval, a joint effort by cardiologists and hepatologists may be useful and significantly improve the clinical course and outcome.

Abstract

Approximately 30% to 70% of patients with cirrhosis have QT interval prolongation. In patients without cirrhosis, QT prolongation is associated with an increased risk of ventricular arrhythmias, such as torsade de pointes (TdP). In cirrhotic patients, there is likely a significant association between the corrected QT (QTc) interval and the severity of liver disease, and possibly with increased mortality. We present a stepwise overview of the pathophysiology and management of acquired long QT syndrome in cirrhosis. The QT interval is mainly determined by ventricular repolarization. To compare the QT interval in time it should be corrected for heart rate (QTc), preferably by the Fridericia method. A QTc interval >450 ms in males and >470 ms in females is considered prolonged. The pathophysiological mechanism remains incompletely understood, but may include metabolic, autonomic or hormonal imbalances, cirrhotic heart failure and/or genetic predisposition. Additional external risk factors for QTc prolongation include medication (IKr blockade and altered cytochrome P450 activity), bradycardia, electrolyte abnormalities, underlying cardiomyopathy and acute illness. In patients with cirrhosis, multiple hits and cardiac-hepatic interactions are often required to sufficiently erode the repolarization reserve before long QT syndrome and TdP can occur. While some risk factors are unavoidable, overall risk can be mitigated by electrocardiogram monitoring and avoiding drug interactions and electrolyte and acid-base disturbances. In cirrhotic patients with prolonged QTc interval, a joint effort by cardiologists and hepatologists may be useful and significantly improve the clinical course and outcome.

참고문헌 (102)

  1. Mann K, Chappelle D, "Let's Twist Again" (1961), Cameo-Parkway Records
  2. Chahal D, "Review article : comprehensive analysis of cirrhotic cardiomyopathy", Aliment Pharmacol Ther, 53, pp.985~998 (2021)
  3. Yoon KT, "Cirrhotic cardiomyopathy", Curr Gastroenterol Rep, 22, pp.45~ (2020)
  4. Kowalski HJ, "The cardiac output at rest in Laennec's cirrhosis", J Clin Invest, 32, pp.1025~1033 (1953)
  5. Bernardi M, "Q-T interval prolongation in cirrhosis : prevalence, relationship with severity, and etiology of the disease and possible pathogenetic factors", Hepatology, 27, pp.28~34 (1998)
  6. Drew BJ, "Prevention of torsade de pointes in hospital settings : a scientific statement from the American Heart Association and the American College of Cardiology Foundation", Circulation, 121, pp.1047~1060 (2010)
  7. Garson A Jr, "How to measure the QT interval : what is normal", Am J Cardiol, 72, pp.14~ (1993)[DOI]
  8. Goldenberg I, "QT interval : how to measure it and what is"normal"", J Cardiovasc Electrophysiol, 17, pp.333~336 (2006)
  9. Panicker GK, "Intra-and interreader variability in QT interval measurement by tangent and threshold methods in a central electrocardiogram laboratory", J Electrocardiol, 42, pp.348~352 (2009)
  10. Hnatkova K, "Precision of QT interval measurement by advanced electrocardiographic equipment", Pacing Clin Electrophysiol, 29, pp.1277~1284 (2006)
  11. Vandenberk B, "Which QT correction formulae to use for QT monitoring", J Am Heart Assoc, 5, pp.e003264~ (2016)
  12. Bazett HC, "An analysis of the time relations of electrocardiograms", Heart, 7, pp.353~370 (1920)
  13. Malik M, "Relation between QT and RR intervals is highly individual among healthy subjects : implications for heart rate correction of the QT interval", Heart, 87, pp.220~228 (2002)
  14. Vandenberk B, "QT correction across the heart rate spectrum, in atrial fibrillation and ventricular conduction defects", Pacing Clin Electrophysiol, 41, pp.1101~1108 (2018)
  15. Fridericia LS, "Die Systolendauer im Elektrokardiogramm bei normalen Menschen und bei Herzkranken", Acta Medica Scandinavica, 53, pp.469~486 (1920)
  16. Rautaharju PM, "Assessment of prolonged QT and JT intervals in ventricular conduction defects", Am J Cardiol, 93, pp.1017~1021 (2004)
  17. Vandenberk B, "A prolonged QTcinterval at the emergency department : should we always be prepared for the worst", J Cardiovasc Electrophysiol, 30, pp.2041~2050 (2019)
  18. Zambruni A, "QT interval correction in patients with cirrhosis", J Cardiovasc Electrophysiol, 18, pp.77~82 (2007)
  19. Główczyńska R, "Pretransplant QT interval : the relationship with severity and etiology of liver disease and prognostic value after liver transplantation", Ann Transplant, 23, pp.622~630 (2018)
  20. Kazankov K, "QT interval corrected for heart rate is not associated with mortality in patients with cirrhosis and ascites", Scand J Gastroenterol, 54, pp.1376~1378 (2019)
  21. U.S. Department of Health and Human Services, "Guidance for Industry: E14 clinical evaluation of QT", QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs, 2005
  22. Sauer AJ, "Long QT syndrome in adults", J Am Coll Cardiol, 49, pp.329~337 (2007)
  23. Priori SG, "Risk stratification in the long-QT syndrome", N Engl J Med, 348, pp.1866~1874 (2003)
  24. van Noord C, "Drug-and nondrug-associated QT interval prolongation", Br J Clin Pharmacol, 70, pp.16~23 (2010)
  25. Giudicessi JR, "The genetic architecture of long QT syndrome : a critical reappraisal", Trends Cardiovasc Med, 28, pp.453~464 (2018)
  26. Wallace E, "Long QT syndrome : genetics and future perspective", Pediatr Cardiol, 40, pp.1419~1430 (2019)
  27. Kannankeril P, "Drug-induced long QT syndrome", Pharmacol Rev, 62, pp.760~781 (2010)
  28. Vandenberg JI, "hERG K(+)channels : structure, function, and clinical significance", Physiol Rev, 92, pp.1393~1478 (2012)
  30. Dessertenne F, "A new chapter of electrocardiography : the progressive variations in the amplitude of the electrocardiogram. 1966", Cardiovasc Drugs Ther, 5, pp.171~190 (1991)
  31. Roden DM, "Incidence and clinical features of the quinidine-associated long QT syndrome : implications for patient care", Am Heart J, 111, pp.1088~1093 (1986)
  32. Makkar RR, "Female gender as a risk factor for torsades de pointes associated with cardiovascular drugs", JAMA, 270, pp.2590~2597 (1993)
  33. Roden DM, "Effects of low potassium or magnesium concentrations on isolated cardiac tissue", Am J Med, 82, pp.18~23 (1987)
  34. Tomaselli GF, "Electrophysiological remodeling in hypertrophy and heart failure", Cardiovasc Res, 42, pp.270~283 (1999)
  35. Halkin A, "Pause-dependent torsade de pointesfollowing acute myocardial infarction : a variant of the acquired long QT syndrome", J Am Coll Cardiol, 38, pp.1168~1174 (2001)
  36. Waldo AL, "Effect of d-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction", Lancet, 348, pp.7~12 (1996)
  37. Vandael E, "Risk factors for QTc-prolongation : systematic review of the evidence", Int J Clin Pharm, 39, pp.16~25 (2017)
  38. Schwartz PJ, "Prevalence of the congenital long-QT syndrome", Circulation, 120, pp.1761~1767 (2009)
  39. Paulussen AD, "Genetic variations of KCNQ1, KCNH2, SCN5A, KCNE1, and KCNE2 in drug-induced long QT syndrome patients", J Mol Med(Berl), 82, pp.182~188 (2004)
  40. Itoh H, "The genetics underlying acquired long QT syndrome : impact for genetic screening", Eur Heart J, 37, pp.1456~1464 (2016)
  41. Roden DM, "Drug-induced prolongation of the QT interval", N Engl J Med, 350, pp.1013~1022 (2004)
  42. Vandael E, "Development of a risk score for QTc-prolongation : the RISQ-PATH study", Int J Clin Pharm, 39, pp.424~432 (2017)
  43. Vandael E, "A smart algorithm for the prevention and risk management of QTc prolongation based on the optimized RISQ-PATH model", Br J Clin Pharmacol, 84, pp.2824~2835 (2018)
  44. Noseworthy PA, "QT interval and long-term mortality risk in the Framingham Heart Study", Ann Noninvasive Electrocardiol, 17, pp.340~348 (2012)
  45. Nielsen JB, "Risk prediction of cardiovascular death based on the QTc interval : evaluating age and gender differences in a large primary care population", Eur Heart J, 35, pp.1335~1344 (2014)
  46. Dessertenne F, "Ventricular tachycardia with 2 variable opposing foci", Arch Mal Coeur Vaiss, 59, pp.263~272 (1966)
  47. Vandael E, "Incidence of torsade de pointes in a tertiary hospital population", Int J Cardiol, 243, pp.511~515 (2017)
  48. Yap YG, "Drug induced QT prolongation and torsades de pointes", Heart, 89, pp.1363~1372 (2003)
  49. Zareba W, "Drug induced QT prolongation", Cardiol J, 14, pp.523~533 (2007)
  50. Hinterseer M, "Beat-tobeat variability of QT intervals is increased in patients with drug-induced long-QT syndrome : a case control pilot study", Eur Heart J, 29, pp.185~190 (2008)
  51. Takasugi N, "Prevalence of microvolt T-wave alternans in patients with long QT syndrome and its association with torsade de pointes", Circ Arrhythm Electrophysiol, 9, pp.e003206~ (2016)
  52. Yamaguchi M, "T wave peak-toend interval and QT dispersion in acquired long QT syndrome:a new index for arrhythmogenicity", Clin Sci(Lond), 105, pp.671~676 (2003)
  53. Topilski I, "The morphology of the QT interval predicts torsade de pointes during acquired bradyarrhythmias", J Am Coll Cardiol, 49, pp.320~328 (2007)
  54. Bal JS, "Prolongation of QTc interval : relationship with etiology and severity of liver disease, mortality and liver transplantation", Liver Int, 23, pp.243~248 (2003)
  55. Zamirian M, "Corrected QT interval and QT dispersion in cirrhotic patients before and after liver transplantation", Arch Iran Med, 15, pp.375~377 (2012)
  56. Adigun AQ, "Effect of cirrhosis and liver transplantation on the gender difference in QT interval", Am J Cardiol, 95, pp.691~694 (2005)
  57. Desai MS, "Bile acid excess induces cardiomyopathy and metabolic dysfunctions in the heart", Hepatology, 65, pp.189~201 (2017)
  58. Desai MS, "Bile acids induce arrhythmias : old metabolite, new tricks", Heart, 99, pp.1629~1630 (2013)
  59. Pu J, "Cardiomyocyte-expressed farnesoid-X-receptor is a novel apoptosis mediator and contributes to myocardial ischaemia", reperfusion injury, 2013, pp.34, 1834~1845
  60. Kawamata Y, "A G protein-coupled receptor responsive to bile acids", J Biol Chem, 278, pp.9435~9440 (2003)
  61. Eblimit Z, "TGR5 activation induces cytoprotective changes in the heart and improves myocardial adaptability to physiologic, inotropic, and pressure-induced stress in mice", Cardiovasc Ther, 36, pp.e12462~ (2018)
  62. Ward CA, "Potassium currents in atrial and ventricular myocytes from a rat model of cirrhosis", Am J Physiol, 273(2 Pt 1), pp.G537~G544 (1997)
  63. Binah O, "Effects of bile acids on ventricular muscle contraction and electrophysiological properties : studies in rat papillary muscle and isolated ventricular myocytes", Naunyn Schmiedebergs Arch Pharmacol, 335, pp.160~165 (1987)
  64. Ytting H, "Prolonged Q-T(c)interval in mild portal hypertensive cirrhosis", J Hepatol, 43, pp.637~644 (2005)
  65. Trevisani F, "QT interval in patients with non-cirrhotic portal hypertension and in cirrhotic patients treated with transjugular intrahepatic porto-systemic shunt", J Hepatol, 38, pp.461~467 (2003)
  66. Fleckenstein JF, "Presence of autonomic neuropathy is a poor prognostic indicator in patients with advanced liver disease", Hepatology, 23, pp.471~475 (1996)
  67. Oka H, "Correlation of altered Q-T interval and sympathetic nervous system dysfunction in diabetic autonomic neuropathy", Eur Neurol, 34, pp.23~29 (1994)
  68. Diedrich A, "Modulation of QT interval during autonomic nervous system blockade in humans", Circulation, 106, pp.2238~2243 (2002)
  69. Zambruni A, "Cardiac electrophysiological abnormalities in patients with cirrhosis", J Hepatol, 44, pp.994~1002 (2006)
  70. Puthumana L, "Prolonged QTc interval and its relationship to autonomic cardiovascular reflexes in patients with cirrhosis", J Hepatol, 35, pp.733~738 (2001)
  71. Tsiompanidis E, "Liver cirrhosis-effect on QT interval and cardiac autonomic nervous system activity", World J Gastrointest Pathophysiol, 9, pp.28~36 (2018)
  72. Vink AS, "Effect of age and sex on the QTc interval in children and adolescents with type 1 and 2 long-QT syndrome", Circ Arrhythm Electrophysiol, 10, pp.e004645~ (2017)
  73. Nakagawa M, "Influence of menstrual cycle on QT interval dynamics", Pacing Clin Electrophysiol, 29, pp.607~613 (2006)
  74. Bai CX, "Nontranscriptional regulation of cardiac repolarization currents by testosterone", Circulation, 112, pp.1701~1710 (2005)
  75. Nakamura H, "Progesterone regulates cardiac repolarization through a nongenomic pathway : an in vitro patch-clamp and computational modeling study", Circulation, 116, pp.2913~2922 (2007)
  76. Gordon GG, "Conversion of androgens to estrogens in cirrhosis of the liver", J Clin Endocrinol Metab, 40, pp.1018~1026 (1975)
  77. Țeranu E, "Q-T interval prolongation in patients with liver cirrhosis", Curr Health Sci J, 44, pp.274~279 (2018)
  78. Torp-Pedersen C, "Dofetilide in patients with congestive heart failure and left ventricular dysfunction. Danish Investigations of Arrhythmia and Mortality on Dofetilide Study Group", N Engl J Med, 341, pp.857~865 (1999)
  79. Henriksen JH, "Increased circulating pro-brain natriuretic peptide(proBNP)and brain natriuretic peptide(BNP)in patients with cirrhosis : relation to cardiovascular dysfunction and severity of disease", Gut, 52, pp.1511~1517 (2003)
  80. Joseph LC, "PKCδcauses sepsisinduced cardiomyopathy by inducing mitochondrial dysfunction", Am J Physiol Heart Circ Physiol, 318, pp.H778~H786 (2020)
  81. Yang YY, "Mechanisms of TNFalpha-induced cardiac dysfunction in cholestatic bile duct-ligated mice : interaction between TNFalpha and endocannabinoids", J Hepatol, 53, pp.298~306 (2010)
  82. Nam SW, "Cardiomyocyte apoptosis contributes to pathogenesis of cirrhotic cardiomyopathy in bile duct-ligated mice", Clin Sci(Lond), 127, pp.519~526 (2014)
  83. Lee SS, "Desensitization of myocardial beta-adrenergic receptors in cirrhotic rats", Hepatology, 12(3 Pt 1), pp.481~485 (1990)
  84. Koshy AN, "Relationship between QT interval prolongation and structural abnormalities in cirrhotic cardiomyopathy : a change in the current paradigm", Am J Transplant, 21, pp.2240~2245 (2021)
  85. Bernardi M, "QT interval prolongation in liver cirrhosis : innocent bystander or serious threat", Expert Rev Gastroenterol Hepatol, 6, pp.57~66 (2012)
  86. Zhao J, "Prevalence, risk factors and inhospital outcomes of QTc interval prolongation in liver cirrhosis", Am J Med Sci, 352, pp.285~295 (2016)
  87. Kim SM, "QT prolongation is associated with increased mortality in end stage liver disease", World J Cardiol, 9, pp.347~354 (2017)
  88. Biselli M, "Development and validation of a scoring system that includes corrected QT interval for risk analysis of patients with cirrhosis and gastrointestinal bleeding", Clin Gastroenterol Hepatol, 17, pp.1388~1397 (2019)
  89. Ko J, "Effect of liver transplantation on QT-interval prolongation and impact on mortality", Int J Cardiol, 326, pp.158~163 (2021)
  90. Lee SH, "Corrected QT interval on the electrocardiogram after liver transplantation : surrogate marker of poor clinical outcomes", PLoS One, 13, pp.e0206463~ (2018)
  91. Tisdale JE, "Development and validation of a risk score to predict QT interval prolongation in hospitalized patients", Circ Cardiovasc Qual Outcomes, 6, pp.479~487 (2013)
  92. Pickham D, "High prevalence of corrected QT interval prolongation in acutely ill patients is associated with mortality : results of the QT in Practice(QTIP)Study", Crit Care Med, 40, pp.394~399 (2012)
  93. Benoit SR, "Risk factors for prolonged QTc among US adults : Third National Health and Nutrition Examination Survey", Eur J Cardiovasc Prev Rehabil, 12, pp.363~368 (2005)
  94. Danielsson BR, "Phenytoin and phenobarbital inhibit human hERG potassium channels", Epilepsy Res, 55, pp.147~157 (2003)
  95. Carranco E, "Carbamazepine toxicity induced by concurrent erythromycin therapy", Arch Neurol, 42, pp.187~188 (1985)
  96. Villeneuve JP, "Cytochrome P450 and liver diseases", Curr Drug Metab, 5, pp.273~282 (2004)
  97. Chvilicek JP, "Diuretic-induced hypokalaemia inducing torsades de pointes", Can J Anaesth, 42, pp.1137~1139 (1995)
  98. Lazzerini PE, "Proton pump inhibitors and serum magnesium levels in patients with torsades de pointes", Front Pharmacol, 9, pp.363~ (2018)
  99. Wong F, "The cardiac response to exercise in cirrhosis", Gut, 49, pp.268~275 (2001)
  100. Viskin S, "Cardiac pacing in the long QT syndrome : review of available data and practical recommendations", J Cardiovasc Electrophysiol, 11, pp.593~600 (2000)
  101. Alvarez CK, "Heart failure as a substrate and trigger for ventricular tachycardia", J Interv Card Electrophysiol, 56, pp.229~247 (2019)[DOI]
  102. Ki Tae Yoon, "β-blockers in advanced cirrhosis: More friend than enemy", Clinical and Molecular Hepatology, 27(3), pp.425~436 (2021), 대한간학회[DOI]

이 간행물의 다른 논문 (18건)

Bismuth-Based Quadruple Therapy for Clarithromycin-Resistant Helicobacter pylori Infection: Effectiveness and Cost-EfficiencyKim Gwang Ha, Lee Moon Wonpp. 807-808How to Optimize the Care Cascade of Hepatitis C Virus InfectionKim Beom Kyungpp. 809-810Forthcoming Step in Gastric Cancer Prevention: How Can Risk Stratification Be Combined with Endoscopic Screening for Gastric Cancer?Hamashima Chisatopp. 811-824A New Paradigm Shift in Gastroparesis ManagementRerknimitr Rungsun, Mekaroonkamol Parit, Tiankanon Kaseneepp. 825-839Chemoprevention of Colitis-Associated Dysplasia or Cancer in Inflammatory Bowel DiseaseChen Yang-Yuan, Hsiao Shun-Wen, Yen Hsu-Hengpp. 840-848
원문 보기